FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Commercial · sales Continues its prescription-drug and contract-manufacturing business and has launched stem-cell-culture skincare.

  • Launched a skincare brand based on stem-cell culture fluid. Source

Roles often seen at this stageSales & marketing · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Dongkoo Bio & Pharma

A pharmaceutical company in prescription drugs such as dermatology products and contract development and manufacturing, which has launched stem-cell-culture skincare.

Cellbloom

Marketed

Derma skincare brand using 3D-cultured human stem-cell culture fluid.

Completion reported

Launched Cellbloom, a skincare brand based on stem-cell culture fluid.

Official role guide

Dongkoo Bio & Pharma careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 동구바이오제약, 더마 스킨케어 브랜드 '셀블룸' 출시 ↗파이낸셜뉴스 · Published 2026-11-11 · Sources checked 2026-11-15 · Original unavailable
  2. 동구바이오제약, 처방약 경쟁력 여전…"신성장동력 성과 본격화" ↗네이트 뉴스 · Published 2026-03-23 · Sources checked 2026-11-15 · Original unavailable